Viking Therapeutics (VKTX) Accumulated Expenses (2014 - 2018)

Viking Therapeutics (VKTX) reported Accumulated Expenses of $34000.0 for Q1 2018, up 54.55% sequentially from $22000.0 in Q4 2017.

Viking Therapeutics (VKTX) Accumulated Expenses (2014 - 2018) Analysis & Trends

Viking Therapeutics (VKTX) has 5 years of Accumulated Expenses data on file, last reported at $34000.0 in Q1 2018.

For the quarter ending Q1 2018, Accumulated Expenses changed N/A year-over-year to $34000.0; the trailing twelve-month figure through Mar 2018 stood at $34000.0 (changed N/A YoY), and the FY2017 full-year result was $22000.0, down 36.95% from the prior year.
Accumulated Expenses climbed to $34000.0 in Q1 2018, from $22000.0 in the prior quarter.
In the past five years, Accumulated Expenses ranged from a high of $183611.0 in Q4 2015 to a low of $9982.0 in Q3 2017.
A 5-year average of $70009.8 and a median of $47113.5 in 2016 frame the typical range for Accumulated Expenses.
Across the five-year window, Accumulated Expenses tumbled 91.37% in 2016 and jumped 467.51% in 2017, its largest moves.
Tracing VKTX's Accumulated Expenses over 5 years: stood at $77222.0 in 2014, then surged by 137.77% to $183611.0 in 2015, then plunged by 81.0% to $34894.0 in 2016, then slumped by 36.95% to $22000.0 in 2017, then surged by 54.55% to $34000.0 in 2018.
Business Quant data shows VKTX's Accumulated Expenses at $34000.0 in Q1 2018, $22000.0 in Q4 2017, and $9982.0 in Q3 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Viking Therapeutics	4.09 Bn	4.09 Bn	-

Download Data